Male circumcision and antiviral drugs appear to sharply reduce HIV infection rate

November 29, 2017

A steep drop in the local incidence of new HIV infections accompanied the rollout of a U.S.-funded anti-HIV program in a large East-African population, according to a study led by researchers at Johns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine.

The study, published Nov. 29 in the New England Journal of Medicine, is the first to track a large group of people before, during and after the start of an HIV prevention program and show that the program is likely working on a large scale. The researchers found that as the program began and matured from the early 2000s until 2016, there was a 42 percent decline in the rate of new HIV infections.

The ongoing HIV prevention program--in Uganda's rural Rakai District on the shore of Lake Victoria--has been funded by the President's Emergency Plan for AIDS Relief (PEPFAR), set up in 2004 by the George W. Bush Administration. The program provides multiple free services, including anti-HIV drugs for infected people, voluntary safe male circumcision, condoms and promotion of risk-reduction sexual practices. These measures are known to reduce HIV transmission and acquisition at an individual level, but their population-wide impact over time in a real-world context has been less clear.

The African region also accounts for almost two-thirds of the global total of new HIV infections, according to the World Health Organization, with 25.6 million people in the region living with HIV in 2016.

"When I started doing research at Rakai in the late 1980s, about a third of people in the trading centers were HIV positive and there was little we could do to prevent a further spread of the virus--but now there's so much more that we can do, and with this study we're finally seeing the beneficial results of these combined interventions," says co-senior author Maria Wawer, MD, professor in the Bloomberg School's departments of Epidemiology and Population, Family and Reproductive Health.

"The results are exciting because they show that the scale-up of these interventions, including adherence to antiretroviral drugs, is possible and can reduce the rate of new HIV infections even in low-resource settings," says lead author Mary Kate Grabowski, PhD, who started the work as an assistant scientist in the Department of Epidemiology at the Bloomberg School and then as an assistant professor in the Department of Pathology at Johns Hopkins School of Medicine.

The co-senior author of the study was Larry W. Chang, MD, MPH, associate professor at Johns Hopkins School of Medicine.

Rakai District was one of the earliest- and worst-hit areas when the HIV/AIDS pandemic emerged in the 1980s. In 1988, Wawer and Ugandan colleagues founded the Rakai Project (re-named the Rakai Health Sciences Program (RHSP) as it expanded) and began conducting surveys and HIV testing among adults (age 15-49) in Rakai communities. This initial work resulted in the Rakai Community Cohort Study (RCCS), which is now one of the largest and oldest HIV surveillance studies tracking the epidemic in sub-Saharan Africa. Scale-up of PEPFAR-funded efforts to reduce HIV mortality and new infections began in the area in 2004.

The current study, based on RCCS data on 34,000 adults enrolled and followed between 1989 and 2016, confirmed the widespread adoption of many of PEPFAR's HIV prevention measures. The use of antiretroviral therapy among infected people rose steadily from 12 percent in the 2006 survey to 69 percent in 2016. The proportion of circumcised men nearly quadrupled from about 15 percent in 1999 to 59 percent in 2016. The proportion of HIV-infected people in whom the amount of virus in their blood (viral load) fell to near zero (at which point transmission is virtually stopped) rose from 42 percent in 2009 to 75 percent in 2016. Evidence of behavioral changes was weaker--the rate of condom use did not rise, for example--but during the study period younger people in the cohort appeared to become much less likely to initiate sex.

The RCCS also tested participants for new HIV infections. The data showed that as coverage of the PEPFAR services increased following their introduction in 2004, the incidence of new HIV infections in the cohort--the number of conversions from HIV-negative to HIV-positive status, on a per-person, per-year basis--began to fall. From 1999 to 2006 the average was 1.17 cases per 100 person-years. By 2016 that figure had fallen to 0.66 cases per 100 person-years. With statistical adjustments for the aging of the cohort and other variables, that represents a net decline of 42 percent.

A fall in HIV incidence was seen among both women and men, although the drop was greater among men--more than 50 percent, compared to about 30 percent for women.

"This difference may have been due to the direct risk-lowering effect of circumcision for men, plus the fact that infected women were more likely than men to use antiretroviral therapy and thus were less likely to transmit the virus to male partners," Grabowski says. "Increasing antiretroviral therapy use among men may help close this gap."

On the whole, Wawer says, "these findings strongly suggest that at the population level there really is a dose-response effect, so that the more prevention services are provided, the more the rate of new infections goes down."

She notes that the Rakai prevention program is beginning to expand its services to include pre-exposure prophylaxis: antiretroviral therapy for people who are HIVnegative to protect them from infection if they have sex with people who are HIV positive.

PEPFAR, which has an annual budget of nearly $7 billion, continues to fund new and existing prevention programs in Africa and other heavily HIV-affected areas. It also funds studies of these prevention programs' impacts. "Preliminary data from other sites in Uganda and elsewhere are consistent with our encouraging findings from Rakai," Grabowski says.
-end-
"HIV Prevention Efforts and Incidence of HIV" in Uganda was written by M.K. Grabowski, D.M. Serwadda, R.H. Gray, G. Nakigozi, G. Kigozi, J. Kagaayi, R. Ssekubugu, F. Nalugoda, J. Lessler, T. Lutalo, R.M. Galiwango, F. Makumbi, X. Kong, D. Kabatesi, S.T. Alamo, S. Wiersma, N.K. Sewankambo, A.A.R. Tobian, O. Laeyendecker, T.C. Quinn, S.J. Reynolds, M.J. Wawer, and L.W. Chang.

Support for the research was provided by the National Institute of Mental Health (grant R01MH107275), the National Institute of Allergy and Infectious Diseases (R01AI110324, U01AI100031, U01AI075115, R01AI110324, R01AI102939, and K01AI125086-01), the National Institute of Child Health and Development (RO1HD070769 and R01HD050180), the World Bank, the Doris Duke Charitable Foundation, the Bill and Melinda Gates Foundation (08113, 22006.02), the Johns Hopkins University Center for AIDS Research (P30AI094189), PEPFAR via the US Centers for Disease Control and Prevention (NU2GGH000817), and a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine and the U.S. Department of Defense.

Johns Hopkins University Bloomberg School of Public Health

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.